Cartilage and bone repair and regeneration using postpartum-derived cells

a postpartum derived cell and cartilage technology, applied in the field of mammalian cell biology and cell culture, can solve the problems of fibrocartilage formation at the site of full thickness defect, fibrocartilage lacks the biomechanical properties of articular cartilage, and failure to persist in the joint on a long-term basis

Inactive Publication Date: 2006-07-13
ETHICON INC
View PDF99 Cites 186 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the subchondral bone tissue is both innervated and vascularized, damage to this tissue is often painful.
The repair reaction induced by damage to the subchondral bone usually results in the formation of fibrocartilage at the site of the full-thickness defect.
Fibrocartilage, however, lacks the biomechanical properties of articular cartilage and fails to persist in the joint on a long term basis.
Partial-thickness defects are caused by mechanical arrangements of the joint which in turn induce wearing of the cartilage tissue within the joint.
In the absence of innervation and vasculature, partial-thickness defects do not elicit repair responses and therefore tend not to heal.
Although painless, partial-thickness defects often degenerate into full-thickness defects.
Cartilage may develop abnormally or may be damaged by disease, such as rheumatoid arthritis or osteoarthritis, or by trauma, each of which can lead to physical deformity and debilitation.
Whether cartilage is damaged from trauma or congenital anomalies, its successful clinical regeneration is often poor at best, as reviewed by Howell, et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Derivation of Cells from Postpartum Tissues

[0293] The objective of this study was to derive populations of cells from placental and umbilical cord tissues. Postpartum umbilical cord and placenta were obtained upon birth of either a full term or pre-term pregnancy. Cells were harvested from 5 separate donors of umbilical cord and placental tissue. Different methods of cell isolation were tested for their ability to yield cells with: 1) the potential to differentiate into cells with different phenotypes, or 2) the potential to provide critical trophic factors useful for other cells and tissues.

[0294] Methods & Materials

[0295] Umbilical cord cell derivation. Umbilical cords were obtained from National Disease Research Interchange (NDRI, Philadelphia, Pa.). The tissues were obtained following normal deliveries. The cell isolation protocol was performed aseptically in a laminar flow hood. To remove blood and debris, the umbilical cord was washed in phosphate buffered saline (PBS; Invi...

example 2

Evaluation of Growth Media for Postpartum-Derived Cells

[0321] Several cell culture media were evaluated for their ability to support the growth of placenta-derived cells. The growth of placenta-derived cells in normal (20%) and low (5%) oxygen was assessed after 3 days using the MTS calorimetric assay.

[0322] Methods & Materials

[0323] Placenta-derived cells at passage 8 (P8) were seeded at 1×103 cells / well in 96 well plates in Growth medium (DMEM-low glucose (Gibco, Carlsbad Calif.), 15% (v / v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, Utah), 0.001% (v / v) betamercaptoethanol (Sigma, St. Louis, Mo.), 50 Units / milliliter penicillin, 50 micrograms / milliliter streptomycin (Gibco)). After 8 hours, the medium was changed as described in Table 2-1, and cells were incubated in normal (20%, v / v) or low (5%, v / v) oxygen at 37° C., 5% CO2 for 48 hours. MTS was added to the culture medium (CELLTITER 96 AQueous One Solution Cell Proliferation Assay, Promega, Madison, Wis.) for 3 hou...

example 3

Growth of Postpartum-Derived Cells in Medium Containing D-Valine

[0332] It has been reported that medium containing D-valine instead of the normal L-valine isoform can be used to selectively inhibit the growth of fibroblast-like cells in culture (Hongpaisan, 2000; Sordillo et al., 1988). The growth of postpartum-derived cells in medium containing D-valine in the absence of L-valine was evaluated.

[0333] Methods & Materials

[0334] Placenta-derived cells (P3), fibroblasts (P9), and umbilical cord-derived cells (P5) were seeded at 5×103 cells / cm2 in gelatin-coated T75 flasks (Corning, Corning, N.Y.). After 24 hours the medium was removed and the cells were washed with phosphate buffered saline (PBS) (Gibco, Carlsbad, Calif.) to remove residual medium. The medium was replaced with a Modified Growth medium (DMEM with D-valine (special order Gibco), 15% (v / v) dialyzed fetal bovine serum (Hyclone, Logan, Utah), 0.001% (v / v) betamercaptoethanol (Sigma), 50 Units / milliliter penicillin, 50 mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This claims benefit of U.S. Provisional Application Ser. No. 60 / 483,264, filed Jun. 27, 2003, the entire contents of which are incorporated by reference herein. Other related applications include the following commonly-owned, co-pending applications, the entire contents of each of which are incorporated by reference herein: U.S. application No. [ETH-5073 NP1], filed Jun. 25, 2004, U.S. application No. [ETH-5073 NP2], filed Jun. 25, 2004, U.S. application No. [ETH-5073 NP3], filed Jun. 25, 2004, U.S. application No. [ETH-5073 NP4], filed Jun. 25, 2004, U.S. application No. [ETH-5073 NP5], filed Jun. 25, 2004, U.S. application No. [ETH-5073 NP7], filed Jun. 25, 2004, and U.S. Provisional Application No. 60 / 555,908 [ETH 5127], filed Mar. 24, 2004. [ETH 5127], filed Mar. 24, 2004.FIELD OF THE INVENTION [0002] This invention relates to the field of mammalian cell biology and cell culture. In particular, the invention relates to cells derived...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/12C12N5/08C12N5/073C12N5/074
CPCA61K35/12A61K45/06C12N5/0607C12N2500/32C12N2500/34C12N2500/44C12N2500/99C12N2501/12C12N2501/21C12N2501/23C12N2502/02C12N2506/02C12N2506/03C12N2509/00C12N2533/50A61K35/51C12N5/0605C12N2500/90C12N2500/95A61K38/18A61K38/1808A61K38/1825A61K38/1833A61K38/1841A61K38/185A61K38/1858A61K38/1866A61K38/1891A61K38/19A61K38/204A61K38/2053A61K38/27A61P1/00A61P1/02A61P1/16A61P1/18A61P13/12A61P17/02A61P19/00A61P19/04A61P19/08A61P19/10A61P21/00A61P25/00A61P25/02A61P25/14A61P25/16A61P25/28A61P27/02A61P27/06A61P29/00A61P35/00A61P37/02A61P37/06A61P39/06A61P43/00A61P7/02A61P9/00A61P9/04A61P9/10C12N5/0606A61K35/50
Inventor KIHM, ANTHONYSEYDA, AGNIESZKADHANARAJ, SRIDEVIWANG, ZIWEIHARMON, ALEXANDERHARRIS, IANMESSINA, DARINMISTRY, SANJAYGOSIEWSKA, ANNA
Owner ETHICON INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap